Coherus生物科技 CHRS 深 沪
等待开盘 06-26 09:30:00 美东时间
1.48
-0.040
-2.63%
华盛通- 最 高1.56
- 今 开1.52
- 成交量 51.39万股
- 最 低 1.48
- 昨 收 1.52
- 总市值 22.83万
- 52周最高 2.6158
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 0.733
- 委 比 19.08%
- 总股本 0.00亿
- 历史最高 38.10
- 量 比 0.62
- 振 幅 5.26%
- 历史最低 0.6603
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Coherus Announces Clinical Collaboration And Supply Agreement With Zumutor To Conduct Phase 1 Trial Of ZM008, NK Checkpoint Anti-LLT1 Monoclonal Antibody In Combination With LOQTORZI
Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripa...
06-24 02:02
Sona Nanotech appoints ex-Coherus executive Michael Fleming to board
Sona Nanotech appoints ex-Coherus executive Michael Fleming to board Sona Nanotech appointed Michael A. Fleming to its board of directors on June 11, 2026. Fleming previously served as EVP, commercial operations, then chief strategy officer at Coherus BioSciences, leading the UDENYCA oncology launch
06-11 19:52
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported progress on its NVG-291 clinical development, including FDA alignment on the RESTORE study parameters for chronic tetraplegia, ongoing CONNECT SCI biomechanical gait analyses, and plans to initiate the RESTORE study in mid-2026. The company listed on Nasdaq under 'NGEN' and strengthened its leadership team with key senior appointments. Financially, NervGen ended Q1 2026 with $16.6M in cash and investments, increased ...
05-18 11:15
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Coherus BioSciences Q1 Adj. EPS $(0.25) Beats $(0.27) Estimate, Sales $12.310M Miss $14.342M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 28.57 percent increase over losses of $(0.35) per share
05-12 04:11
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12
Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $12.
05-12 02:40
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Coherus BioSciences Charts Leaner Path After Earnings Call
Coherus Biosciences (($CHRS)) has held its Q4 earnings call. Read on for the ma...
04-03 08:14
Insights into Coherus Oncology Q4 Earnings
The Q4 earnings report for Coherus Oncology (NASDAQ:CHRS) was released on Monda...
03-10 04:18
Coherus BioSciences Q4 Adj. EPS $(0.34), Inline, Sales $12.748M Miss $13.944M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of
03-10 04:17
